Biogenic Nanoparticles for Cancer Theranostics outlines the synthesis of biogenic nanoparticles to become cancer theranostic agents. The book also discusses their cellular interaction and uptake, pharmacokinetics, biodistribution, drug delivery efficiency, and other biological effects. Additionally, the book explores the mechanism of their penetration in cancerous tissue, its clearance, and its metabolism. Moreover, the in vitro and in vivo toxicological effects of biogenic nanoparticles are discussed. This book is an important reference source for materials scientists and biomedical scientists who are looking to increase their understanding of how biogenic nanoparticles are being used for a range of cancer treatment types.
Metal nanoparticles have traditionally been synthesized by classical physico-chemical methods which have many drawbacks, such as high energy demand, high cost and potential ecotoxicity. As a result, the biosynthesis of metal nanoparticles is gaining increasing prominence. Biosynthesis approaches to metal nanoparticles are clean, safe, energy efficient and environment friendly.
- Explains the synthesis methods and applications of biogenic nanoparticles for cancer theranostics
- Outlines the distinctive features of biogenic nanoparticles that make them effective cancer treatment agents
- Assesses the major challenges of using biogenic nanoparticles on a mass scale
2. Biogenic nanoparticles: synthesis, mechanism, characterization and applications
3. Phytonanotechnology: A greener approach for biomedical applications
4. Microbial enzymes mediated biosynthesis of metal nanoparticles
5. Green nanotechnology: Isolation of bioactive molecules and modified approach of bio-synthesis
6. Green synthesis of Inorganic Nanoparticles and their cancer theranostics applications
7. Biosynthesized silver nanoparticles as cancer theranostic agents
8. Biosynthesized gold nanoparticles as cancer theranostic agents
9. Mechanisms underlying the anticancer applications of biosynthesized nanoparticles
10. Hurdles for green nanomaterials as future cancer nanomedicine
Chittaranjan Patrareceived his B.Sc (1995) and M.Sc (1997) in Chemistry from the University of Burdwan, W.B. He was awarded the "Dr. Mrigendranath Ghosh Gold Medal for obtaining first class and first rank in B.Sc Chemistry (Hons) Examination in 1995 from The University of Burdwan, India.He completed his Ph.D. in Chemistry in 2003 as CSIR Fellow(April 1998- March 2003) fromNational Chemical Laboratory (NCL), Pune.Thereafter, he received his postdoctoral experience (March 2003-October 2004) as 'Nanotechnologist' from Bar-Ilan University, Ramat-Gan, Israel. After that he moved to Mayo Clinic, Department of Biochemistry and Molecular Biology in October 2004 as postdoc followed by Assistant Professor in the same Department.Here Dr. Patra explored the field of nanobiotechnology for cancer and angiogenesis. Dr. Patra moved to CSIR-IICT-Hyderabad in 2010 after receiving prestigious Ramanujan Fellowship, from DST-New Delhi. Currently, Dr. Patra is working as Principal Scientistat Department of Applied Biology, CSIR-Indian Institute of Chemical Technology (IICT) and his research group is pursuing various nanomedicine research projects aimed at developing advanced nanomaterials and nanoparticles-based drug delivery systems (DDS) for treatment of cancer, cardiovascular and ischemic disease.
Irshad Ahmad is Associate Professor of Life Sciences Department at King Fahd University of Petroleum & Minerals, Saudi Arabia. His research focuses in the area of green nanobiotechnology and cellular metabolics.
Muhammad Ayaz is a Lecturer at the Department of Pharmacy, University of Malakand, Pakistan. His research focuses on nanomaterials for drug delivery.
Khalil, Ali Talha
Ali Talha Khalil is a Lecturer in Materials Science at Qarshi University, India. His research focuses on using diverse nanotechnological and biotechnological approaches to answer various health care and industry related problems.
Sudip Mukherjee is a Research Fellow in Bioengineering at Rice University, USA. His research focuses on developing novel platforms of next generation therapeutics and diagnostics to improve the treatment of human diseases.
Muhammad Ovais is a Research Scientist at the CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), China. His research focuses on nanomedicine and cancer theranostics.